Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Safety Check

Selectivity as a distinguishing feature

    • Neurology
    • Partner Content
    • RX
  • 5 minute read

Like any form of intervention in the human immune system, therapy with Ozanimod carries certain risks. In particular, infections and adverse cardiac effects represent previously known side effects of treatment with S1P receptor modulators. However, the pivotal studies of ozanimod, as well as other data since their completion, suggest a comparatively favorable safety profile [1–3].

Overall, the incidence of serious adverse effects of ozanimod has been low. In both pivotal studies, the SUNBEAM and RADIANCE studies, comparable values were seen in all three treatment groups (Table 1). The serious adverse reactions, which were registered most frequently, were appendicitis and sinus tachycardia. There were no drug-associated deaths in either population [1,2]. This favorable safety profile is perpetuated by the data collected to date from the open label DAYBREAK study with consistent incident rates of serious adverse events and no drug-related deaths [4]. In the indirect comparison by Swallow E et al. [5] with fingolimod, a widely used S1P receptor modulator, showed a significantly lower incidence of adverse drug reactions with Ozanimod therapy. In particular, cardiac events after initial administration and low blood lymphocyte counts occurred less frequently when the new agent was used [5]*. This could be due to the higher selectivity of ozanimod.

* No direct comparisons of the active ingredients exist.

A narrow ridge

Due to the decreased exposure of sphingosine 1-phosphate receptors on lymphocytes under S1PReceptor modulator therapy, they accumulate in the lymph nodes while their numbers in the blood circulation decrease [6]. This known, dose-dependent effect of lymphocyte redistribution was also observed under Ozanimod therapy and on the one hand conditions the efficacy of the drug, but on the other hand could promote infections and weaken the infection defense. In both pivotal studies, lymphocyte counts decreased by approximately 57% during the first three months and then settled at a stable level (Table 2). Overall, there were 29 cases in the ozanimod 1 mg and 4 cases in the ozanimod 0.5 mg therapy group in which lymphocyte counts fell below 0.2 × 109/L, but this did not result in any serious or opportunistic infections. In the indirect comparison with the agent fingolimod, the circulating white blood cell count was less affected by ozanimod after one year of therapy, but efficacy with respect to clinical endpoints was comparable in the analysis [5].

This could indicate a reduced susceptibility to infections during treatment with ozanimod, which reached statistical significance at least for the frequency of liver infections after two years of therapy. In both the SUNBEAM and RADIANCE studies, infections, including serious infections and herpes infections, were evenly distributed across the treatment groups [1,2]. Thus, despite its direct intervention in the immune system, the new agent does not appear to be inferior to therapy with interferon β1a with respect to the risk of infection. Also with regard to malignant diseases, no new concerns were raised by the pivotal studies. Nevertheless, these risks, which are based on the mode of action of ozanimod, certainly need to be considered and monitored in the longer term.

Matters of the Heart

Because subtype 1 S1P receptors are also expressed on atrial myocytes, therapy with S1P receptor modulators such as ozanimod may lead to adverse cardiac effects, especially during the dose escalation phase. In particular, bradycardia and AV blockade pose potentially life-threatening risks and require cardiac monitoring after initial administration, as well as slow up-dosing of the drug over several days. Under extended monitoring, no second- or even third-degree AV block occurred in either pivotal study of ozanimod after initial administration, or during its subsequent course. Furthermore, there were no clinically significant bradycardias and only a small proportion of patients required cardiac monitoring lasting more than 6 hours [1,2]. In the follow-up study, no clinically significant bradycardias or AV block images occurred until the most recent interim analysis, even after switching medication from interferon β1a to ozanimod or increasing the dose [4].

The selective mechanism of action of ozanimod may play an essential role in the favorable cardiac risk profile compared with fingolimod. This was demonstrated in the indirect comparison of the two agents by Swallow et al. [5]* postulated and potentially represents an important difference in comparison with other substances of the same class. For example, in the pivotal trials for fingolimod, a significantly greater proportion of patients had a pulse below 45/minute and more cardiac events were reported during monitoring. Conduction pathologies, first-grade AV block, and conditions requiring monitoring for more than 6 hours occurred significantly less frequently with ozanimod therapy (fig. 1). In addition, blood pressure decreased less after initial administration of the new agent [5].

* No direct comparisons of the active ingredients exist.

* Proportion of participants with serious adverse drug reactions (study duration 12 months).
** Proportion of participants with serious adverse drug reactions (study duration 24 months).
◊ Proportion of participants with serious adverse drug reactions (data from an interim analysis with a mean follow-up duration of 18.5 months; all participants received ozanimod 1 mg daily during this time).
 

Favorable safety profile due to selectivity?

Cardiac side effects and infections remain important safety risks with this S1P receptor modulator, but appear to be comparatively rare. The selective targeting of ozanimod may provide a mechanistic explanation for this and serve as an example for further development of new drugs in this area. 

Literature:

1 Cohen JA, Comi G, Selmaj KW, et al: Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019; 18(11): 1021-1033.
2 Comi G, Kappos L, Selmaj KW, et al: Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019; 18(11): 1009-1020.
3 Selmaj KW, et al: Long-term Efficacy of Ozanimod in Relapsing Multiple Sclerosis in DAYBREAK: An Open-Label Extension of the Phase 3 SUNBEAM and RADIANCE Trials. 6th Congress of the European Academy of Neurology, Sept 2020; Virtual presentation.
4. Steinman L: Ozanimod Efficacy in Relapsing Multiple Sclerosis Supported by Open-Label Long-Term Extension of Two Phase 3 Trials. Presentation at the Annual Meeting of the American Academy of Neurology; Philadelphia, Pennsylvania 2019.
5. Swallow E, Patterson-Lomba O, Yin L, et al: Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis. J Comp Eff Res. 2020; 9(4): 275-285.
Matloubian M, Lo CG, Cinamon G, et al: Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004; 427(6972): 355-360.
 
Partner
  • 2000px-bristol-myers_squibb_logo
Related Topics
  • MS Therapy in Transition
Previous Article
  • Efficacy Check

Multiple levels of effectiveness

  • Neurology
  • Partner Content
  • RX
View Post
Next Article
  • Non-chemotherapy-induced neutropenia

Isolated neutropenia: a clinical picture with many faces

  • CME continuing education
  • Education
  • Hematology
  • Oncology
  • Pharmacology and toxicology
  • RX
View Post
You May Also Like
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
View Post
  • 4 min
  • Prurigo nodularis

Retrospective analyses of large data sets from everyday practice

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
View Post
  • 3 min
  • Public Health

Outpatient care in Switzerland: situation report

    • General Internal Medicine
    • Practice Management
    • Prevention and health care
    • RX
View Post
  • 5 min
  • Practice Management

Improved quality of care aims for satisfied patients

    • CME continuing education
    • General Internal Medicine
    • Practice Management
    • Prevention and health care
    • RX
    • Studies
View Post
  • 30 min
  • Chemsex - MSM, sex, chrystal meth & co.

Medical and psychosocial perspectives

    • CME continuing education
    • General Internal Medicine
    • Infectiology
    • Pharmacology and toxicology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • RX
View Post
  • 3 min
  • Bladder cancer

Tuberculosis vaccination reduces recurrences

    • Congress Reports
    • Oncology
    • Pneumology
    • Prevention and health care
    • RX
    • Studies
    • Urology
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.